Lu-177-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer

作者：Fendler Wolfgang P; Kratochwil Clemens; Ahmadzadehfar Hojjat; Rahbar Kambiz; Baum Richard P; Schmidt Matthias; Pfestroff Andreas; Luetzen Ulf; Prasad Vikas; Heinzel Alexander; Heuschkel Martin; Ruf Juri; Bartenstein Peter; Krause Bernd J^*

来源：Nuklearmedizin, 2016, 55(3): 123-128.

• Consensus
• lutetium
• PSMA
• radioligand therapy
• prostate cancer

Radioligand therapy (RLT) using Lu-177 labelled inhibitors of the prostate-specific membrane antigen (Lu-177-PSMA) is performed in patients with metastatic castration-resistant prostate cancer (mCRPC) after exhaustion of other options. German University Clinics offer RLT since 2013 on a compassionate use basis. The present consensus document includes recommendations for RLT with Lu-177-PSMA-617. These consensus statements were developed by an expert panel formed by the German Society of Nuclear Medicine (DGN) in December 2015. Statements include recommendations for indication, baseline tests, therapy protocol, concomitant therapy, dosimetry, and follow-up. Consensus recommendations aim to inform the attending medical staff, standardize Lu-177-PSMA-617 RLT, and improve quality of individual patient care.

• 出版日期2016